

NIH funding opportunities

01 July 2024 (#21)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[NOT-TW-24-008](#) Notice of Pre-Application Webinar for Fogarty HIV Research Training Program for LMIC Institutions (D43 Clinical Trial Optional) and Planning Grant for Fogarty HIV Research Training Program for LMIC Institutions (D71 Clinical Trial Not Allowed). Date of virtual webinar – July 15, 2024, 9 AM – 10:30 AM EST. Please Register for the FIC D71 and D43 Program Pre-Application Webinar at <https://nih.zoomgov.com/meeting/register/vJIsdeyqgz8jGhsVw4NzXZvAbn9IxnAY4xw>.

Parent Announcements

[NOT-OD-24-099](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **[PA-20-185](#)** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **[PA-20-184](#)** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **[PA-20-183](#)** Research Project Grant (Parent R01 Clinical Trial Required)
- **[PA-20-200](#)** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **[PA-20-195](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **[PA-20-194](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **[PA-20-196](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-AI-24-050](#) Epigenetic Modulation of HBV cccDNA and integrated HBV DNA (iDNA): Implications for Epigenetic Treatment Strategies Against HBV in HIV/HBV Co-Infection. The purpose of this NOSI is to invite applications for innovative basic, translational, and clinical research to identify and address epigenetic treatment strategies for achieving HBV cure in PLWH. This notice applies to due dates on or after September 7, 2024 and subsequent receipt dates through May 7, 2027. Submit applications

for this initiative using one of the NOFOs listed in the NOSI or any reissues of these announcements through the expiration date of this notice.

[NOT-AI-24-053](#) Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential. The objective of this NOSI is to support the discovery and development of small molecule compounds (MW < 2 kDa) with activity against viral targets that can be administered orally as monotherapy or in combination with other drugs to treat infections caused by viruses of pandemic potential. Activities are anticipated to range from early discovery and optimization of lead series with activity against a specific pathogen or viral family, to late-stage preclinical development and IND-enabling profiling of specific drug candidates. Collaboration with pharma to access chemical starting points and critical medicinal chemistry, regulatory and drug development expertise is strongly encouraged. Applications should include multidisciplinary activities appropriate to the project's stage of discovery and development. This notice applies to application receipt dates on or after October 5, 2024, and subsequent receipt dates through July 16, 2027. Submit applications for this initiative using one of the NOFOs listed or any reissues of these announcements through the expiration date of this notice.

[NOT-OD-24-146](#) Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health. The objective of this NOSI is to encourage research grant applications that address adherence to recommended treatment and prevention regimens and maintenance of behaviors to promote health outcomes. Applications may address health behavior initiation, execution, and/or maintenance through mechanistic studies, efficacy trials, or implementation research. Descriptive and intervention research may address relevant determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged. This NOSI applies to due dates on or after July 15, 2024 and subsequent receipt dates through July 14, 2027. Submit applications for this initiative using one of the NOFOs listed or any reissues of these announcements through the expiration date of this notice.

Notice of Funding Opportunity (NOFO)

[PAR-24-243](#) Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed). The purpose of this NOFO is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children's language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children's language development and/or impairment, and predictors thereof. This NOFO requires a Community Engagement (CE) Plan, which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a CE Plan will be considered incomplete and will be withdrawn. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).

Due Dates: October 05, 2024 through to June 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

[PAR-24-244](#) Advancement and Innovation in Measurement of Language Development and Predictors (R21 Clinical Trial Not Allowed). The purpose of this NOFO is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children's language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children's language development and/or impairment, and predictors thereof. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP).

Due dates: October 16, 2024 through to June 16, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. These direct cost caps are exclusive of facilities and administrative costs of consortia, when applicable.

[RFA-DA-25-057](#) Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required). The purpose of this notice of funding opportunity (NOFO) is to support the development of neuromodulatory devices with behavioral treatment component as a treatment for Stimulant Use Disorder (StUD). Given the high rates of relapse and poor treatment outcomes in StUD, the objective is to target patients with vulnerable phenotype including those with reported qualitatively high levels of impulsivity, compulsivity, and cognitive dysfunction. Moreover, this NOFO concentrates on advancing treatment modalities combinations: pairing non-invasive neuromodulation (including, but not limited to transcranial magnetic stimulation, transcranial direct current stimulation, vagal stimulation, alternating current stimulation, low-intensity focused ultrasound, and others) with either known efficacious behavioral interventions (e.g., contingency management, cognitive behavioral therapy) or novel treatments. Applications should plan to move devices to their next step in the Food and Drug Administration (FDA) approval process, with the ultimate goal of generating new, FDA-approved device-based treatments and/or combination products for StUD.

Due dates: November 27, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent Due Date November 27, 2024.

Budget: NIDA intends to commit \$2,000,000 in FY 2025 to fund three to five awards. Application budgets are limited to \$500K per year for direct costs but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[RFA-MH-25-195](#) Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional). This NOFO is intended to stimulate and support research that will use behavioral measures and computational methods to define novel clinical signatures that can be used for individual-level prediction and clinical decision making in mental disorders. A multi-component approach is proposed in which grantees will (1) identify and/or develop behavioral tasks (and other types of measures, as appropriate) that are optimized for measurement of individual differences in individuals with or at risk of developing mental disorders; (2) collect the data from novel clinical cohorts and/or identify existing datasets that include behavioral data and other data that are typically available in the clinical record; (3) derive novel clinical signatures that incorporate behavioral measures and information derived from the clinical record, and are informative for clinical purposes; and (4) partner with the existing Data Coordinating Center (DCC) (funded under previous [RFA-MH-23-106](#)), which is responsible for coordinating the harmonization of methods, aggregation of data, analysis of combined data, and creation of a data infrastructure to support data sharing with the scientific community. Applicants may propose new cohorts from one or more populations targeted to specific clinical groupings (e.g., mood/anxiety disorders, disorders of behavior regulation, psychosis) and/or care delivery settings, may leverage data from existing clinical research cohorts that have appropriate data structures, or may use a combination of approaches with new and existing data.

Due dates: October 18, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent Due Date September 18, 2024.

Budget: NIMH intends to commit \$15 million total in FY 2025 for this NOFO to fund up to 6 U01 awards. Application budgets are limited to no more than \$2,500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[RFA-NS-24-035](#) Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed). This initiative will solicit applications that propose the development and early stage validation of novel small animal models and/or human cellular microphysiological systems of HIV infection that better recapitulate the complex interactions that occur between cells of the CNS and the immune system in people with HIV (PWH). The goal of this initiative is to promote a significant improvement in the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression.

Due dates: December 02, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent Due Date November 01, 2024.

Budget: The following NIH components intend to commit the following amounts in FY 2025: NINDS, \$3,000,000, 2-3 awards; NIMH, \$2,000,000, 1-2 awards; NIDA, \$1,000,000, 1 award. Application budgets are limited to \$600,000 in direct costs/year and need to reflect the actual needs of the proposed project. The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed four years, with no more than two years for the R61 phase and no more than three years for the R33 phase.

Faculty of Medicine and Health Sciences Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO) 009 K th Floor, Teaching Block, Tygerberg Campus.	Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street
Enquiries: cdevries@sun.ac.za / fmhsgmo@sun.ac.za	Enquiries: research@sun.ac.za
Add "Interest in NIH opportunity" in the subject line. Add the notice number in the text of the email.	